Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase (ALK)‐rearranged metastatic (stage IIIB/IV) non‐small‐cell lung cancer (NSC...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Hida, Toyoaki, Seto, Takashi, Horinouchi, Hidehito, Maemondo, Makoto, Takeda, Masayuki, Hotta, Katsuyuki, Hirai, Fumihiko, Kim, Young Hak, Matsumoto, Shingo, Ito, Masayuki, Ayukawa, Koichi, Tokushige, Kota, Yonemura, Masataka, Mitsudomi, Testuya, Nishio, Makoto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125456/
https://ncbi.nlm.nih.gov/pubmed/29959809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13721
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia